Lancet
-
Randomized Controlled Trial
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
Etrolizumab is a humanised monoclonal antibody that selectively binds the β7 subunit of the heterodimeric integrins α4β7 and αEβ7. We aimed to assess etrolizumab in patients with moderately-to-severely active ulcerative colitis. ⋯ Genentech.